Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addressing ethnic disparities in neurological research in the United Kingdom: An example from the prospective multicentre COVID-19 Clinical Neuroscience Study.
van Wamelen DJ, Rota S, Hartmann M, Martin NH, Alam AM, Thomas RH, Dodd KC, Jenkins T, Smith CJ, Zandi MS, Easton A, Carr G, Benjamin LA, Lilleker JB, Saucer D, Coles AJ, Wood N, Ray Chaudhuri K, Breen G, Michael BD; COVID-CNS consortium. van Wamelen DJ, et al. Clin Med (Lond). 2024 Apr 19;24(3):100209. doi: 10.1016/j.clinme.2024.100209. Online ahead of print. Clin Med (Lond). 2024. PMID: 38642613 Free article.
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
Gonzalez-Robles C, Bartlett M, Burnell M, Clarke CS, Haar S, Hu MT, Huxford B, Jha A, Lawton M, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, van Wamelen D, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Weil RS, Schrag A; EJS ACT-PD Consortium. Gonzalez-Robles C, et al. Among authors: van wamelen d. Mov Disord. 2024 Feb;39(2):433-438. doi: 10.1002/mds.29691. Epub 2023 Dec 22. Mov Disord. 2024. PMID: 38140767
Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.
Gonzalez-Robles C, Weil RS, van Wamelen D, Bartlett M, Burnell M, Clarke CS, Hu MT, Huxford B, Jha A, Lambert C, Lawton M, Mills G, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Schrag A; EJS ACT-PD Consortium. Gonzalez-Robles C, et al. Among authors: van wamelen d. J Parkinsons Dis. 2023;13(6):1011-1033. doi: 10.3233/JPD-230051. J Parkinsons Dis. 2023. PMID: 37545260 Free PMC article. Clinical Trial.
Atypical motor presentation of Huntington's Disease.
Śmiłowska K, van Wamelen D. Śmiłowska K, et al. Among authors: van wamelen d. Neurol Neurochir Pol. 2023;57(5):450-451. doi: 10.5603/PJNNS.a2023.0025. Epub 2023 Apr 20. Neurol Neurochir Pol. 2023. PMID: 37078132 Free article. No abstract available.
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
Leta V, van Wamelen DJ, Aureli F, Metta V, Trivedi D, Cortelli P, Rodriguez-Blazquez C, Rizos A, Ray Chaudhuri K. Leta V, et al. Among authors: van wamelen dj. J Neural Transm (Vienna). 2023 Jul;130(7):925-930. doi: 10.1007/s00702-023-02603-y. Epub 2023 Apr 10. J Neural Transm (Vienna). 2023. PMID: 37036498 Free PMC article.
54 results